BridGene Holding Corporation is a biomedical company based on novel and high-throughput chemical proteomic platform. We are focused on discovering novel targets and developing therapeutics for unmet medical needs to improve human life. Our end product would be small molecular drugs to treat cancers. During the long drug development process, we may collaborate with pharmaceutical companies to co-develop new drugs.